Antitumor Activities of KRN7000 in NS-1 Myeloma-Bearing Mice
- Author:
Hong-Min YAN
1
,
2
;
Ming-Zhe HAN
;
Jun-Ling HAN
;
Cheng-Wen LI
;
Han-Zhi LIU
Author Information
1. Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin 300020, China
2. Department of Hematology, The General Hospital of Air Force, PLA, Beijing 100036, China.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2001;9(4):343-346
- CountryChina
- Language:Chinese
-
Abstract:
To explore the antitumor activities of KRN7000 in a NS-1 myeloma-bearing mice and the underlying mechanisms, cytotoxic activities of the spleen cells treated with KRN7000 in vivo and in vitro were examined with Yac-1 (a NK-sensitive cell line) and NS-1 (a NK-insensitive cell line) as the targeted cells. The life span of NS-1 myeloma-bearing mice was observed after treating with KRN7000 and combined with cyclophosphamide (CTX). Furthermore, toxicities of KRN7000 administration on liver and kidney were evaluated. The results showed that KRN7000 enhanced NK cytotoxic activities of spleen cells. Around 20% of NS-1-bearing mice survived after KRN7000 administration and the survival rate reached up to 80% of NS-1-bearing mice when KRN7000 was used in combination with CTX at a dose of 100 mg/kg (P < 0.005). KRN7000, at a dose of 100 micro g/kg, had no toxic effects on liver and kidney. These findings suggest that KRN7000 might be a promosing agent in tumor immunotherapy.
